SPRY ALERT: Securities Fraud Class Action Launched Against ARS Pharmaceuticals, Inc. - October 5, 2026 Deadline
Levi & Korsinsky, LLP announced a securities class action against ARS Pharmaceuticals (NASDAQ: SPRY) on behalf of investors who purchased SPRY securities between March 9, 2026 and June 24, 2026. The complaint alleges defendants made misleading statements about the timeline for expanded CVS Caremark insurance coverage for neffy; after ARS disclosed June 24 that coverage was not received by the guided July 1 deadline, the stock fell from $10.54 to $8.02, a one-day decline of over 23.9%. CVS Caremark has reportedly reserved its decision on expanded neffy coverage until January 2027, leaving the reimbursement overhang unresolved.
Key figures
- Class period
- March 9, 2026 to June 24, 2026
- One day decline pct
- 23.9%
- Stock price 2026 06 24 close
- 10.54
- Stock price 2026 06 25 close
- 8.02
- Cvs caremark decision deferred to
- January 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.